Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

8

Deferred tax assets, net 167,368 176,619

Other current assets 108,106 43,267

Total current assets 1,588,163 1,422,025

PROPERTY AND EQUIPMENT, net 501,575 500,396

GOODWILL 471,127 476,515

INTANGIBLE ASSETS, net 753,286 817,828

DEFERRED TAX ASSETS, net 171,865 141,752

OTHER ASSETS 169,589 147,753

$3,655,605 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $1,023,104 $1,237,169

Accounts payable 81,323 91,437

Accrued expenses 723,728 677,184

Total current liabilities 1,828,155 2,005,790

LONG-TERM DEBT 2,729 3,788

DEFERRED TAX LIABILITIES, net 72,088 56,540

OTHER LIABILITIES 180,539 138,084

Total liabilities 2,083,511 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 713 700

Additional paid-in capital 2,050,035 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (413,166) (624,128)

Accumulated other comprehensive

income 129,294 148,703

Total stockholders' equity 1,572,094 1,302,067

$3,655,605 $3,506,269
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... 2015 , ... Drug companies increasingly are adopting a business ... in its new report that the U.S. will generate the greatest demand for ... most market demand. , BCC Research examines plant-derived drugs in its report, ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, ... developing treatments for urological and related conditions, announced today ... planned private placement convertible note financing, raising a total ... tranches totaling $3.175 million. Josh ... from this private placement are intended to be used ...
(Date:9/2/2015)... ZIONA, Israel , September 2, ... TASE: BVXV) today announced the intent of the National Institute ... National Institutes of Health (NIH) within the Department of Health ... trial to be held in the United States ... the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), ...
(Date:9/2/2015)... Whitehouse, NJ (PRWEB) , ... September 02, 2015 ... ... key Technical Services Staff members will be attending Pharma Ed Resources upcoming ... and respected group of industry leading speakers, this timely conference will provide Updates ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3
... Fred Alger Management, Inc. (Alger),a leading asset ... M.D. as Vice President, Senior Analyst/Co-Portfolio Manager for,Alger ... and,pharmaceutical industries., David received his Doctor of ... was Chief Medical Resident. While in Pennsylvania David,served ...
... obsolete? EnviroChip™ white papers show how consumers like you can ... damaging your engine. , ... Denver (PRWEB) July 28, ... that EnviroChip™, a revolutionary fuel harmonizing microchip, can eliminate a consumer,s ...
... University of Pennsylvania have created a one-step, repeatable ... or motifs with adjustable features, size and shape ... took advantage of the elastic instability of a ... When exposed to a solvent, circular pores ...
Cached Biology Technology:David Farhadi, M.D. to Join Alger as Vice President, Senior Analyst/Co-Portfolio Manager 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 2Penn researchers demonstrate a flexible, 1-step assembly of nanoscale structures 3
(Date:8/18/2015)... Aug. 17, 2015 Research and Markets ... the "Global Biometric Authentication & Identification Market: ... & Forecast, 2015-2020" report to their offering. ... identification systems market is expected to grow at ... 2020 and generate over $25 billion (approximately) by ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... Sperm whales weigh up to 50 tons, and the smallest ... the same success story: They both have developed the ability ... Now Danish researchers show that the biosonar of toothed ... they live in very different environments and vary extremely in ...
... that glioma is derived from brain tumor stem cells, ... are still unclear. The potential of neural stem cells ... been considered, but has not been confirmed. A team ... Hospital of Nanjing Medical University, China found that doxycycline-induced ...
... active immunization in Alzheimer,s disease can increase the ... but it is easy to induce meningoencephalitis, which ... To enhance anti-Aβ antibody generation and induce a ... from the First Affiliated Hospital of China Medical ...
Cached Biology News:Bats and whales behave in surprisingly similar ways 2Bats and whales behave in surprisingly similar ways 3
Request Info...
... Hematopoietic stem cells (HSC) are well-characterized tissue-specific ... and are responsible for the life-long maintenance ... cells that reside in adult bone marrow ... can also be found in cord blood, ...
Anti-TWIK-1 Immunogen: Purified peptide from amino acids 53-69 of human TWIK-1 (Accession number O00180)....
EDG-6 (1)...
Biology Products: